Key result
Current evidence supports the use of intravenous ferric carboxymaltose to improve clinical status and well-being in symptomatic patients with HFrEF and iron deficiency, whereas oral iron is ineffective.
Why the study?
Does intravenous ferric carboxymaltose improve symptoms, exercise capacity, and quality of life compared to oral iron or placebo in symptomatic HFrEF patients with iron deficiency?
Does intravenous ferric carboxymaltose improve symptoms, exercise capacity, and quality of life compared to oral iron or placebo in symptomatic HFrEF patients with iron deficiency?
No takes yet. Share an insight, caveat, or question.
This editorial defends the use of intravenous ferric carboxymaltose for treating iron deficiency in HFrEF, emphasizing its proven benefits over ineffective oral iron supplementation.
Doehner et al. (2019) conducted a letter in Heart failure with reduced ejection fraction (HFrEF) and iron deficiency. Intravenous ferric carboxymaltose (FCM) vs. Oral iron therapy was evaluated. Current evidence supports the use of intravenous ferric carboxymaltose to improve clinical status and well-being in symptomatic patients with HFrEF and iron deficiency, whereas oral iron is ineffective.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: